1. Pink Sheet
  2. >>R&D

Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

 
• By Emily Hayes

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

SC1810_Nobel Award_1094864642_1200.jpg

Inventor of the groundbreaking CTLA-4 checkpoint inhibitor Yervoy, James P. Allison, said he learned he had been awarded the Nobel Prize in Physiology or Medicine, along with PD-L1 pioneer Tasuko Honjo, through a call from his son at 5:30 a.m. on Oct. 1.

The Karolinska Institute's Nobel Assembly announced that day that James Allison, aged 70, of the MD Anderson Cancer Center in Houston, Texas, and Tasuko Honjo, aged 76 and a professor at Kyoto University in Japan, would share the award for the discovery and application of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.